CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: Involving activation of PI3K/Akt signaling

► CpG-ODN administration attenuated ischemia/reperfusion-induced myocardial infarction. ► CpG-ODN improved cardiac function after myocardial reperfusion up to 14 days. ► CpG-ODN administration increased Akt and GSK-3β phosphorylation in the myocardium. ► PI3K inhibition or Akt deficiency abolished CpG-ODN-induced cardioprotection.